<DOC>
	<DOCNO>NCT02062489</DOCNO>
	<brief_summary>The current study multicentre , randomize , double-blind , prospective clinical trial stratify patient HER2 status cancer ( negative positive ) sponsor researcher . The trial design evaluate effectiveness tamoxifen adjuvant therapy ER ( ER-α ) /PR negative , ER-β positive operable breast cancer patient . 688 female ER ( ER-α ) /PR negative , ER-β ( wild type ER-β1 ) positive operable breast cancer patient undergone neoadjuvant chemotherapy directly modify radical mastectomy breast-conserving surgery randomly ( 1:1 ) enrol receive tamoxifen ( 20 mg per day ) placebo ( 2 # per day ) within 6 week postoperative chemotherapy and/or radiation therapy need ( accord 2013 NCCN breast cancer guideline ) . If breast tumor 's HER2 positive , patient receive target therapy ( Herceptin ) combine tamoxifen placebo . The follow-up time eight year . The aim trial evaluate effectiveness tamoxifen adjuvant therapy ER ( ER-α ) /PR negative , ER-β positive operable breast cancer patient compare DFS OS tamoxifen group placebo group determine whether percentage positive ER-β expression associate response hormone therapy breast cancer .</brief_summary>
	<brief_title>Evaluation Tamoxifen 's Efficacy ER/PR Negative , ER-beta Positive Operable Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>The patient sign write informed consent The patient present operable unilateral invasive breast cancer without distant metastasis ( stage I , II , III ) The breast tumor 's positive ER/PR rate &lt; 1 % , positive ERbeta1 rate ≥10 % IHC . The patient history neoadjuvant hormone therapy . The patient normal cardiac function echocardiography . The patient ' ECOG score ≤02 . Female patient ≥ 18yrs , ≤ 65yrs . The patient nonpregnant , disposed practice contraception whole trial . The patient underwent neoadjuvant chemotherapy plus surgery directly modify radical mastectomy breastconserving surgery ( plus sentinel lymph node biopsy axillary lymph node dissection ) diagnosis breast cancer . The patient underwent chemotherapy , radiation therapy target therapy ( herceptin ) surgery accord 2013 NCCN guideline . The result patient ' blood test follow : Hb≥90g/L ; WBC≥4.0×109/L ; Plt≥100×109/L ; Neutrophils≥1.5×109/L ; ALT AST ≤ triple normal upper limit ; TBIL ≤ 1.5 time normal upper limit ; Creatinine ≤ 1.25 time normal upper limit . The patient cancer time history cancer except controlled skin basal cell carcinoma skin squamous cell carcinoma carcinoma situ cervix uterus ; The patient active infection suitable chemotherapy ; The patient severe noncancerous disease . The patient history neoadjuvant hormone therapy . The patient bilateral breast cancer DCIS metastatic breast cancer . The patient undergoing current administration anticancer therapy , attend clinical trial . The patient pregnant lactational , refuse practice contraception whole trial . The patient special condition ca n't understand write informed consent , demented hawkish . The patient allergic history contraindication tamoxifen .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>breast cancer ,</keyword>
	<keyword>tamoxifen ,</keyword>
	<keyword>ER/PR negative , ER-beta positive</keyword>
</DOC>